Are salmeterol's beneficial effects on corticosteroid action in the airways executed at the epithelial barrier?

Respirology

Volumn 18, Issue 8, 2013, Pages 1165-1166

  Heijink, Irene H ^a,b,c   Van Den Berge, Maarten ^b,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GRIAC Research Center   (Netherlands)

Author keywords

airway epithelium; asthma; chronic obstructive pulmonary disease; inflammation

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CIGARETTE SMOKE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FORMOTEROL; SALMETEROL;

AIRWAY REMODELING; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISSOLUTION; EDITORIAL; ELECTRIC RESISTANCE; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FUNCTION; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFLAMMATION; SPUTUM;

AIRWAY EPITHELIUM; ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; INFLAMMATION;

ALBUTEROL; ANDROSTADIENES; BRONCHI; CELL MEMBRANE PERMEABILITY; EPITHELIAL CELLS; HUMANS;

EID: 84886833376     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12180     Document Type: Editorial

References (11)

1. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2009; 151: 517-527.
2. Chung KF, Caramori G, Adcock IM,. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur. J. Clin. Pharmacol. 2009; 65: 853-871.
3. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337: 1405-1411.
4. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943.
5. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 2005; 172: 704-712.
6. Kirby S, Falcoz C, Daniel MJ, et al. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. Eur. J. Clin. Pharmacol. 2001; 56: 781-791.
7. Haghi M, Traini D, Postma DS, et al. Mediated fluticasone uptake across CALU-3 cells by salmeterol as combination powder inhaler. Respirology 2013; 18: 1191-1195.
8. Nawijn MC, Hackett TL, Postma DS, et al. E-cadherin: gatekeeper of airway mucosa and allergic sensitization. Trends Immunol. 2011; 32: 248-255.
9. Heijink IH, Brandenburg SM, Postma DS, et al. Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery. Eur. Respir. J. 2012; 39: 419-428.
10. Hoshino M, Ohtawa J,. Effects of budesonide/formoterol combination therapy versus budesonide alone on airway dimensions in asthma. Respirology 2012; 17: 639-646.
11. Borchard G, Cassara ML, Roemele PE, et al. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J. Pharm. Sci. 2002; 91: 1561-1567.